Artelo Biosciences Inc
ARTL
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.75M
Close$
$-0.03
104.4% downside
Current Fair Value
104.4% downsideOvervalued by 104.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.75 Million |
|---|---|
| Enterprise Value | $-1,394,726.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.47 |
| Beta | -0.07 |
| Outstanding Shares | 2,712,000 |
Return
| Return on Equity | -253.57% |
|---|---|
| Return on Assets | -196.18% |
| Return on Invested Capital | -240.87% |
Valuation & Multiples
| P/E Ratio | -0.1 |
|---|---|
| PEG | 0.39 |
| Price to Sales | - |
| Price to Book Ratio | 0.76 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.12 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.04 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.72
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$-0.78
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.17%▲ 1.73% |
|---|---|
| Total Invested | $345,671▲ 186.63% |
| Investors Holding | 10▲ 1.00% |
ESG Score
No data
About Artelo Biosciences Inc
3 employeesArtelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting lipid signaling pathways including the endocannabinoid system. Artelo is rap...